{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-051847","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.520747+00:00","generated_at":"2026-05-20T18:29:12.727624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Replimune Q4 net loss $74.1M; RP1 BLA on track for July 22 PDUFA","bullets":["Net loss Q4 $74.1M, FY $247.3M; cash $483.8M, runway into Q4 2026 excluding revenue.","BLA for RP1+nivolumab in advanced melanoma on schedule; PDUFA July 22, 2025; no advisory committee.","Commercial infrastructure fully built and ready for launch; distribution channels established.","R&D Q4 $54.0M (+27% YoY); SG&A Q4 $25.4M (+57% YoY) driven by pre-launch scaling.","Investor day June 24; confirmatory Phase 3 IGNYTE-3 enrolling 400 patients globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-051847","json":"https://secwatch.observer/filing/0001104659-25-051847.json","markdown":"https://secwatch.observer/filing/0001104659-25-051847.md","text":"https://secwatch.observer/filing/0001104659-25-051847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925051847/0001104659-25-051847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925051847/tm2515645d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T18:29:12.727624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}